developing transformative therapeutic products for large unmet needs in procedure-based medicine that are favorable for partnership.
accelerating medical innovation to patients through risk‑reward sharing partnerships.
Our partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products we help develop.
Our two late-stage flagship products are designed to address large unmet needs associated with the treatment of atherosclerotic artery disease, the leading cause of death worldwide, and hypertension, the leading contributing risk factor for morbidity and mortality worldwide.
Virtue SAB is a patented drug/device combination product for the treatment of artery disease that delivers a proprietary extended release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for a coating or a permanent implant.
BackBeat CNT™ is a patented bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain lowered blood pressure long-term.
Virtue® SAB is not approved for commercial use in the US
BackBeat CNT™ is not approved for commercial use in the US
© 2022 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01